Prediction of early response to overall treatment for schizophrenia: A functional magnetic resonance imaging study
Open Access
- 30 January 2019
- journal article
- research article
- Published by Wiley in Brain and Behavior
- Vol. 9 (2) , e01211
Abstract
Introduction: Treatment response at an early stage of schizophrenia is of considerable value with regard to future management of the disorder; however, there are currently no biomarkers that can inform physicians about the likelihood of response.Objects: We aim to develop and validate regional brain activity derived from functional magnetic resonance imaging (fMRI) as a potential signature to predict early treatment response in schizophrenia.Methods: Amplitude of low‐frequency fluctuation (ALFF) was measured at the start of the first/single episode resulting in hospitalization. Inpatients were included in a principal dataset (n = 79) and a replication dataset (n = 44). Two groups of healthy controls (n = 87; n = 106) were also recruited for each dataset. The clinical response was assessed at discharge from the hospital. The predictive capacity of normalized ALFF in patients by healthy controls, ALFFratio, was evaluated based on diagnostic tests and clinical correlates.Results: In the principal dataset, responders exhibited increased baseline ALFF in the left postcentral gyrus/inferior parietal lobule relative to non‐responders. ALFFratio of responders before treatment was significantly higher than that of non‐responders (p < 0.001). The area under the receiver operating characteristic curve was 0.746 for baseline ALFFratio to distinguish responders from non‐responders, and the sensitivity, specificity, and accuracy were 72.7%, 68.6%, and 70.9%, respectively. Similar results were found in the independent replication dataset.Conclusions: Baseline regional activity of the brain seems to be predictive of early response to treatment for schizophrenia. This study shows that psycho‐neuroimaging holds promise for influencing the clinical treatment and management of schizophrenia.Keywords
Funding Information
- National Natural Science Foundation of China (81801675, 81571651)
This publication has 64 references indexed in Scilit:
- Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multiple-treatments meta-analysisThe Lancet, 2013
- Neural markers of negative symptom outcomes in distributed working memory brain activity of antipsychotic-naive schizophrenia patientsInternational Journal of Neuropsychopharmacology, 2013
- An fMRI-Based Neurologic Signature of Physical PainNew England Journal of Medicine, 2013
- Correlation between Early Subjective Response to Antipsychotics and the Number of Hospitalizations and Hospitalization Days in a Period of 10–11 Years in Schizophrenia PatientsNeuropsychobiology, 2012
- Should the PANSS Be Rescaled?Schizophrenia Bulletin, 2009
- Comparative remission rates of schizophrenic patients using various remission criteriaProgress in Neuro-Psychopharmacology and Biological Psychiatry, 2008
- How effective are second-generation antipsychotic drugs? A meta-analysis of placebo-controlled trialsMolecular Psychiatry, 2008
- Correlation Between the Amplitude of Cortical Activation and Reaction Time: A Functional MRI StudyAmerican Journal of Roentgenology, 2004
- Functional connectivity in the motor cortex of resting human brain using echo‐planar mriMagnetic Resonance in Medicine, 1995
- A common action of clozapine, haloperidol, and remoxipride on D1- and D2-dopaminergic receptors in the primate cerebral cortex.Proceedings of the National Academy of Sciences, 1994